Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Papzimeos, zopapogene imadenovec-drba
Synonyms :
Zopapogene
Class :
Gene Therapies, Pulmonary
Brand Name :
Papzimeos, zopapogene imadenovec-drba
Synonyms :
Zopapogene
Class :
Gene Therapies, Pulmonary
Adult
Dosage Forms & Strengths
Injection (SC suspension)
5x 10^11 particle units/ml single-dose vial
Safety and efficacy not recommended
Refer to the adult dosing
Immunotherapy based on nonreplicating adenoviral vectors that expresses a fusion antigen of specific HPV protein regions produced in cells infected with HPV 6 and HPV 11.
In individuals with recurrent respiratory papillomatosis, it is intended to trigger an immune response against the proteins of HPV 6 and HPV 11.
Frequency defined
>50%
Chills
Injection site reactions
Fatigue
Pyrexia
>10-50%
Myalgia
Headache
1-10%
Vomiting
Hyperhidrosis
Bruising
Dizziness
Blurred vision
Tachycardia
Diarrhea
Dyspnea
Pruritus
None
Contraindications
None
Cautions
Injection site reactions
Thrombotic events
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion in human breastmilk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
The purpose of PAPZIMEOS is to help patients with recurrent respiratory papillomatosis mount an immune response against the proteins of HPV 6 and HPV 11.
Pharmacodynamics:
The activation of T cell responses specific to HPV 6 and HPV 11 was greater in RRP patients who showed a clinical response to therapy, according to 30 patients assessed six weeks after treatment.
The mean fold-change from baseline was 164.9 vs 5.1, indicating a decrease or removal of the need for surgical debulking within the year after therapy completion.
The mean fold-change for responders was 61.5, whereas that of non-responders was 11.5 after 12 weeks after therapy.
Pharmacokinetics:
Absorption:
It has peak plasma concentration of 2.114 ng/ml.
It is used through subcutaneous route as injection form only.
Choose the lateral areas of the thigh and upper arm to receive the injection.
Clean the injection site with an alcohol swab and let it dry for at least 30 seconds.
Refrain from going near wounds, scars, edema, possible infections, or recent SC injection sites.
To guarantee delivery in SC space, put the needle at an angle.
Use an alcohol swab to clean the area once more and avoid massaging the injection site.
Follow these measures for one to two weeks following the injection. Place any potentially contaminated items from the injection site, such as dressings that may contain patient body fluids or waste, in a sealable bag and dispose of them with ordinary garbage.
Maintain good hand hygiene if you come into close touch with patient waste.
For around twenty-four hours following treatment, keep your hands away from the injection site and the bandages.
Generic Name: zopapogene
Why do we use zopapogene?
PAPZIMEOS is indicated for the management of recurrent respiratory papillomatosis (RRP) in adults.
It is a non-replicating immunotherapy based on adenoviral vectors.
PAPZIMEOS is the first and only FDA-approved therapy that targets the underlying causative mechanism of RRP.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
